Contract research organization has 175 Phase III programs ongoing, firm tells analysts Sept. 16 at the Bear Stearns health care conference in New York (1"The Pink Sheet" Sept. 13, p. 6)
You may also be interested in...
The discontinuation of a Lilly/Solvay cardiovascular development program in March is showing up with a six-month delay in Covance operating results with spill-over effects on the image and predictability of the CRO segment.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials